Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Medley: Avelumab Combinations in Advanced Malignancies
NCT02554812Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Modified DNA Oligonucleotides
- Countries
- 8
01
Overview
A Phase 2 trial of avelumab, utomilumab, ivuxolimab, PD-0360324, vidutolimod in non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (HNSCC), triple-negative breast cancer (TNBC), gastric cancer (GC), sponsored by Pfizer. Started Nov 2015; status: terminated.
02
Drugs
avelumabutomilumabivuxolimabPD-0360324vidutolimod
03
Conditions
non-small cell lung cancer (NSCLC)melanomasquamous cell carcinoma of the head and neck (HNSCC)triple-negative breast cancer (TNBC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02554812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02554812.